Amgen bought ChemoCentryx ChemoCentryx from 10/20/22

User image

Vladimir Petenev

News editor
press@blackterminal.com

Amgen completed its acquisition of ChemoCentryx for $3.7 billion, or $52 per share.

ChemoCentryx

Review

Source:

{source} pictogram

investors.amgen.com

Vladimir Petenev

News editor

Write your comment first

News feed

VTB is ready to stop retail unsecured lending

12/3/24 VTBR

Yandex Go expands geographical presence in Uzbekistan

12/3/24 YDEX

Yandex bought the technology platform Pruffme

12/3/24 YDEX

Shareholders of Polyus approved dividends

12/2/24 PLZL

Alfa Bank wants to recover $77.3 mln from Nornickel

12/2/24 GMKN

SMZ's bona fide minority shareholders can expect compensation

12/2/24 MGNZ

China completes construction of the last section of the Siberia Power Grid

12/2/24 GAZP

Shareholders of Sebcement approved dividends

12/2/24 SKCM

Lenta acquires the chain of drogeries Smile of the Rainbow

12/2/24 LENT

Mosgorlombard's revenue grew 4.5 times in January-November

12/2/24 MGKL